Literature DB >> 31046114

Maintenance lenalidomide in primary CNS lymphoma.

J L Rubenstein1, H Geng2, K Vu3, G Mannis4, P Formaker3, J Hwang5, P N Munster6, B Damato7.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 31046114      PMCID： PMC8887569          DOI： 10.1093/annonc/mdz142

Source DB:  PubMed          Journal:  Ann Oncol        ISSN： 0923-7534            Impact factor:   32.976


× No keyword cloud information.
  6 in total

1.  Lenalidomide Maintenance Compared With Placebo in Responding Elderly Patients With Diffuse Large B-Cell Lymphoma Treated With First-Line Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone.

Authors:  Catherine Thieblemont; Hervé Tilly; Maria Gomes da Silva; Rene-Olivier Casasnovas; Christophe Fruchart; Franck Morschhauser; Corinne Haioun; Julien Lazarovici; Anida Grosicka; Aurore Perrot; Judith Trotman; Catherine Sebban; Dolores Caballero; Richard Greil; Koen van Eygen; Amos M Cohen; Hugo Gonzalez; Reda Bouabdallah; Lucie Oberic; Bernadette Corront; Bachra Choufi; Armando Lopez-Guillermo; John Catalano; Achiel Van Hoof; Josette Briere; Jose Cabeçadas; Gilles Salles; Philippe Gaulard; Andre Bosly; Bertrand Coiffier
Journal:  J Clin Oncol       Date:  2017-04-20       Impact factor: 44.544

2.  The elderly left behind-changes in survival trends of primary central nervous system lymphoma over the past 4 decades.

Authors:  Joe S Mendez; Quinn T Ostrom; Haley Gittleman; Carol Kruchko; Lisa M DeAngelis; Jill S Barnholtz-Sloan; Christian Grommes
Journal:  Neuro Oncol       Date:  2018-04-09       Impact factor: 12.300

3.  Lenalidomide in combination with intravenous rituximab (REVRI) in relapsed/refractory primary CNS lymphoma or primary intraocular lymphoma: a multicenter prospective 'proof of concept' phase II study of the French Oculo-Cerebral lymphoma (LOC) Network and the Lymphoma Study Association (LYSA)†.

Authors:  H Ghesquieres; M Chevrier; M Laadhari; O Chinot; S Choquet; C Moluçon-Chabrot; P Beauchesne; R Gressin; F Morschhauser; A Schmitt; E Gyan; K Hoang-Xuan; E Nicolas-Virelizier; N Cassoux; V Touitou; M Le Garff-Tavernier; A Savignoni; I Turbiez; V Soumelis; C Houillier; C Soussain
Journal:  Ann Oncol       Date:  2019-04-01       Impact factor: 32.976

4.  Phase 1 investigation of lenalidomide/rituximab plus outcomes of lenalidomide maintenance in relapsed CNS lymphoma.

Authors:  James L Rubenstein; Huimin Geng; Eleanor J Fraser; Paul Formaker; Lingjing Chen; Jigyasa Sharma; Phoebe Killea; Kaylee Choi; Jenny Ventura; John Kurhanewicz; Clifford Lowell; Jimmy Hwang; Patrick Treseler; Penny K Sneed; Jing Li; Xiaomin Wang; Nianhang Chen; Jon Gangoiti; Pamela N Munster; Bertil Damato
Journal:  Blood Adv       Date:  2018-07-10

5.  High-dose methotrexate for elderly patients with primary CNS lymphoma.

Authors:  Jay-Jiguang Zhu; Elizabeth R Gerstner; David A Engler; Maciej M Mrugala; Whitney Nugent; Kristin Nierenberg; Fred H Hochberg; Rebecca A Betensky; Tracy T Batchelor
Journal:  Neuro Oncol       Date:  2008-08-29       Impact factor: 12.300

6.  Low-dose lenalidomide maintenance after induction therapy in older patients with primary central nervous system lymphoma.

Authors:  Khoan Vu; Gabriel Mannis; Jimmy Hwang; Huimin Geng; James L Rubenstein
Journal:  Br J Haematol       Date:  2019-02-03       Impact factor: 6.998
  6 in total
  2 in total

1.  Lenalidomide and Rituximab Regimen Combined With Intravitreal Methotrexate Followed by Lenalidomide Maintenance for Primary Vitreoretinal Lymphoma: A Prospective Phase II Study.

Authors:  Yan Zhang; Xiao Zhang; Dongmei Zou; Jingjing Yin; Li Zhang; Xuan Wang; Congwei Jia; Wei Wang; Danqing Zhao; Daobin Zhou; Wei Zhang; Meifen Zhang
Journal:  Front Oncol       Date:  2021-06-24       Impact factor: 6.244

Review 2.  On point in primary CNS lymphoma.

Authors:  Mazie Tsang; Joseph Cleveland; James L Rubenstein
Journal:  Hematol Oncol       Date:  2020-07-03       Impact factor: 5.271
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.